Two separate studies were compared to assess the impact of high dose vaccination at multiple anatomic sites in terms of immunogenicity, safety and preliminary efficacy of CimaVax-EGF in advanced NSCLC patients. The gene discussed is EGF; the disease is non-small cell lung carcinoma.